In a phase I clinical trial of the anti-LAG3/anti-PD1 bispecific tebotelimab, objective responses were observed in multiple solid tumor types, including PD1-refractory disease, and in LAG3+ non-Hodgkin lymphomas (65). This evidence concerns the gene LAG3 and non-Hodgkin lymphoma.